Zobrazeno 1 - 10
of 327
pro vyhledávání: '"Miller-Larsson A"'
Publikováno v:
International Journal of COPD, Vol Volume 12, Pp 3055-3064 (2017)
Christer Janson,1 Georgios Stratelis,1,2 Anna Miller-Larsson,3 Tim W Harrison,4 Kjell Larsson5 1Respiratory, Allergy and Sleep Research Unit, Department of Medical Sciences, Uppsala University, Uppsala, Sweden; 2Respiratory, Inflammation and Autoimmu
Externí odkaz:
https://doaj.org/article/73039059b297418998fa58e5d0142a63
Autor:
Wang X, Nelson A, Weiler ZM, Patil A, Sato T, Kanaji N, Nakanishi M, Michalski J, Farid M, Basma H, LeVan TD, Miller-Larsson A, Wieslander E, Muller KC, Holz O, Magnussen H, Rabe KF, Liu X, Rennard SI
Publikováno v:
Journal of Inflammation Research, Vol 2013, Iss default, Pp 109-119 (2013)
Xingqi Wang,1 Amy Nelson,1 Zachary M Weiler,1 Amol Patil,1 Tadashi Sato,1 Nobuhiro Kanaji,1 Masanori Nakanishi,1 Joel Michalski,1 Maha Farid,1 Hesham Basma,1 Tricia D LeVan,1 Anna Miller-Larsson,2 Elisabet Wieslander,2 Kai-Christian Muller,3 Olaf Hol
Externí odkaz:
https://doaj.org/article/6822ea6f0b4d48fba818ab3bee495bcc
Autor:
Fang Q, Schulte NA, Kim H, Kobayashi T, Wang X, Miller-Larsson A, Wieslander E, Toews ML, Liu X, Rennard SI
Publikováno v:
Journal of Inflammation Research, Vol 2013, Iss default, Pp 25-33 (2013)
Qiuhong Fang,1,2 Nancy A Schulte,3 Huijung Kim,4 Tetsu Kobayashi,5 Xingqi Wang,2 Anna Miller-Larsson,6 Elisabet Wieslander,6 Myron L Toews,3 Xiangde Liu,2 Stephen I Rennard21Pulmonary and Critical Care Department, Beijing Shijitan Hospital, Capital M
Externí odkaz:
https://doaj.org/article/bf3b635fa32e43aa869e5060784918a3
Publikováno v:
In Pulmonary Pharmacology & Therapeutics June 2018 50:47-56
Publikováno v:
In European Journal of Pharmacology 15 May 2013 708(1-3):60-67
Autor:
Håkansson, Hanna Falk, Smailagic, Amir, Brunmark, Charlott, Miller-Larsson, Anna, Lal, Harbans
Publikováno v:
In Pulmonary Pharmacology & Therapeutics October 2012 25(5):399-406
Publikováno v:
In Pulmonary Pharmacology & Therapeutics June 2012 25(3):201-207
Autor:
Brange, Charlotte, Smailagic, Amir, Jansson, Anne-Helene, Middleton, Brian, Miller-Larsson, Anna, Taylor, John D., Silberstein, David S., Lal, Harbans
Publikováno v:
In Pulmonary Pharmacology & Therapeutics 2009 22(1):20-26
Publikováno v:
Pulmonary Pharmacology & Therapeutics, 50, 47-56. ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD
Background COPD patients have increased risk of pneumonia when treated with fluticasone propionate (FP), whereas this is generally not the case with budesonide (BUD) treatment. We hypothesized that BUD and FP differentially affect the expression of i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd4b969ed0f164fb11fbb5cfd051ed31
https://doi.org/10.1016/j.pupt.2018.04.002
https://doi.org/10.1016/j.pupt.2018.04.002
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Inhaled corticosteroids (ICSs) treatment combined with long-acting β2-adrenoceptor agonists (LABAs) reduces the risk of exacerbations in COPD, but the use of ICSs is associated with increased incidence of pneumonia. There are indications that this a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a0aa69315afe7d6e56c72f173ab1416
https://doi.org/10.2147/copd.s143656
https://doi.org/10.2147/copd.s143656